Drug · Small Molecule

Lenalidomide

CI-DRUG-00000335Explore in graph →NCIt C2668 CHEMBL848 CIViC Approved

Regulatory

Approvals (21)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory15 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Efficacy supplement 2019-05-28 (see label)	approved	May 28, 2019	openfda
US FDA	—	Efficacy supplement 2017-09-15 (see label)	approved	Sep 15, 2017	openfda
US FDA	—	Efficacy supplement 2017-02-22 (see label)	approved	Feb 22, 2017	openfda
US FDA	—	Efficacy supplement 2015-02-17 (see label)	approved	Feb 17, 2015	openfda
US

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	247	94	138	844	21	EU, US	Dec 27, 2005	2002-03
Non-Hodgkin Lymphoma	Approved	Phase 4	213	78	116	589	4	US	Dec 27, 2005	Apr 1, 2002
Multiple Myeloma	Approved	Phase 4	131	47	87	373	1	US	Dec 27, 2005	Apr 1, 2002
Leukemia	Approved	Phase 4	14	7	6	123	1	US

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CRBN Mutation1
Lenalidomide + Pomalidomide

Clinical trials

Trials with this intervention (863)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 863 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02180711	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	active not recruiting	Phase 1 / Phase 2	113	Acerta Pharma BVINDUSTRY	3	Sep 28, 2026	clinicaltrials
NCT03223610	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	recruiting

Molecule

Record

Kind: Small Molecule
Mechanism: CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
Targets: 4 genes
UNII: F0P408N6V4
Aliases: 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione, CC 5013, CC-5013, CC5013, CDC 501, CDC-501, Lenalidomida, Lenalidomide, Lenalidomide accord, Lenalidomide Krka, Lenalidomide Krka d.d., Lenalidomide Krka d.d. Novo mesto, Lenalidomide mylan, NSC-747972, Revlimid, REVLIMID, SYP-1512

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (8)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L04AX04	Immunosuppressants
ATC (WHO)	L04AX07	Immunosuppressants